ALDX ALDEYRA THERAPEUTICS INC revenue, earnings and financials

For the quarter ended June 30, 2026, ALDEYRA THERAPEUTICS INC reported revenue of n/a, net income of −$5.45M and diluted EPS of −$0.09; for the fiscal year ended December 2025 revenue was n/a.

ALDX annual revenue and earnings

• Fiscal year ended Dec 2025: revenue n/a, gross profit n/a, operating income −$35.3M, net income −$33.8M (margin n/a), EPS −$0.56
• Fiscal year ended Dec 2024: revenue n/a, gross profit n/a, operating income −$60.1M, net income −$55.9M (margin n/a), EPS −$0.94
• Fiscal year ended Dec 2023: revenue n/a, gross profit n/a, operating income −$42.8M, net income −$37.5M (margin n/a), EPS −$0.64
• Fiscal year ended Dec 2022: revenue n/a, gross profit n/a, operating income −$62.7M, net income −$62.0M (margin n/a), EPS −$1.06
• Fiscal year ended Dec 2021: revenue n/a, gross profit n/a, operating income −$56.2M, net income −$57.8M (margin n/a), EPS −$1.07

ALDX quarterly revenue and earnings

• Quarter ended Jun 30, 2026: revenue n/a, net income −$5.45M, EPS −$0.09
• Quarter ended Mar 31, 2026: revenue n/a, net income −$3.45M, EPS −$0.06
• Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income −$6.46M, EPS −$0.10
• Quarter ended Sep 30, 2025: revenue n/a, net income −$7.69M, EPS −$0.13
• Quarter ended Jun 30, 2025: revenue n/a, net income −$9.77M, EPS −$0.16
• Quarter ended Mar 31, 2025: revenue n/a, net income −$9.93M, EPS −$0.17
• Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$15.8M, EPS −$0.27
• Quarter ended Sep 30, 2024: revenue n/a, net income −$15.1M, EPS −$0.25
• Quarter ended Jun 30, 2024: revenue n/a, net income −$16.8M, EPS −$0.28
• Quarter ended Mar 31, 2024: revenue n/a, net income −$8.08M, EPS −$0.14
• Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$4.75M, EPS −$0.08
• Quarter ended Sep 30, 2023: revenue n/a, net income −$8.19M, EPS −$0.14
• Quarter ended Jun 30, 2023: revenue n/a, net income −$8.99M, EPS −$0.15
• Quarter ended Mar 31, 2023: revenue n/a, net income −$15.6M, EPS −$0.27
• Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$12.9M, EPS −$0.22
• Quarter ended Sep 30, 2022: revenue n/a, net income −$14.6M, EPS −$0.25
• Quarter ended Jun 30, 2022: revenue n/a, net income −$17.8M, EPS −$0.30
• Quarter ended Mar 31, 2022: revenue n/a, net income −$16.8M, EPS −$0.29
• Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income −$15.8M, EPS −$0.27
• Quarter ended Sep 30, 2021: revenue n/a, net income −$15.8M, EPS −$0.27

ALDX cash flow, buybacks and dividends

• Fiscal year ended Dec 2025: operating cash flow −$33.3M, share buybacks n/a
• Fiscal year ended Dec 2024: operating cash flow −$43.2M, share buybacks n/a
• Fiscal year ended Dec 2023: operating cash flow −$30.3M, share buybacks n/a
• Fiscal year ended Dec 2022: operating cash flow −$56.6M, share buybacks n/a
• Fiscal year ended Dec 2021: operating cash flow −$42.6M, share buybacks n/a

ALDX balance sheet

• Jun 30, 2026: cash n/a, total assets $47.5M, total liabilities $9.66M, shareholders' equity $37.9M
• Mar 31, 2026: cash n/a, total assets $66.5M, total liabilities $24.3M, shareholders' equity $42.2M, long-term debt $0
• Dec 31, 2025: cash $70.0M, total assets $72.1M, total liabilities $27.8M, shareholders' equity $44.3M, long-term debt $0
• Sep 30, 2025: cash $59.3M, total assets $77.8M, total liabilities $28.6M, shareholders' equity $49.2M, long-term debt $0
• Jun 30, 2025: cash $41.2M, total assets $85.0M, total liabilities $29.7M, shareholders' equity $55.3M, long-term debt $0
• Mar 31, 2025: cash $50.4M, total assets $93.2M, total liabilities $29.6M, shareholders' equity $63.6M, long-term debt $15.1M
• Dec 31, 2024: cash $54.5M, total assets $105M, total liabilities $33.6M, shareholders' equity $71.0M, long-term debt $15.0M
• Sep 30, 2024: cash $68.1M, total assets $117M, total liabilities $32.2M, shareholders' equity $85.1M, long-term debt $15.0M

Is ALDX profitable?

No. ALDEYRA THERAPEUTICS INC lost $23.1M over the last four quarters.

What is ALDX's EPS?

Diluted earnings per share over the last four quarters were −$0.38; −$0.09 in the latest quarter.

ALDX ownership and insider trades · All stocks